Semaglutide Medications For Type 2 Diabetes Reduce Risk Of Kidney Disease

Health care consumers with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (1.0 milligrams of semaglutide given in injection form) experienced a 24% lower risk of severe kidney outcomes and death from cardiovascular or kidney causes compared to those on placebo. Those on Ozempic also showed a slower rate of kidney-function decline, plus an 18% lower risk of heart attack and other major cardiovascular events.

Overall, the risk of death from any cause was 20% lower for those taking Ozempic. These individuals also reported a lower percentage of serious adverse events from Ozempic (49.6 . . .